Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139 BRL | -2.17% |
|
0.00% | +24.77% |
28/06 | PHILIPS NV : JP Morgan reiterates its Neutral rating | ZD |
27/06 | Chinese-owned chipmaker Nexperia invests $200 mln in European expansion | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 117.99 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.77% | 2.36TCr | - | ||
+4.18% | 21TCr | B | ||
+8.00% | 19TCr | B- | ||
+31.86% | 16TCr | B- | ||
+33.21% | 11TCr | A- | ||
+2.28% | 6.43TCr | A- | ||
+21.14% | 5.57TCr | B+ | ||
+0.11% | 4.84TCr | B+ | ||
-6.76% | 3.78TCr | A | ||
+0.78% | 3.56TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PHIA Stock
- PHGN34 Stock
- Ratings Philips NV